DOYLESTOWN, Pa., Nov. 9 /PRNewswire-FirstCall/ -- The Quigley Corporation announced today that on November 7th, 2005, its wholly owned subsidiary Quigley Pharma received four additional Investigational New Animal Drug (INAD) numbers, from the Center for Veterinary Medicine of the Food and Drug Administration.
The company’s naturally derived QR-441A can now be tested upon dogs, cats, horses and companion birds. The formula has previously been tested in a combination of ten efficacious in-vitro and in-vivo studies (in-vivo studies were conducted on ferrets), under the direction of Professor John Oxford, Dr. Rob Lambkin and Sebastien Bossuyt at Retroscreen Virology, Queen Mary’s School of Medicine & Dentistry, University of London, UK.
Dr. Richard Rosenbloom, Quigley Pharma’s Chief Operations Officer stated: “Prompted by the new data upon the H3N8 Equine (horse) flu’s cross over to dogs, we can not only test QR-441A upon chickens, turkeys and ducks but have received permission from the FDA to test upon companion animals: horses, dogs, cats and birds. We believe that the mechanism of action of this all-natural compound may prevent transmission within species as well as to other species. Pets, especially dogs, have the most intimate contact with humans on a daily basis. In addition to our concerns for our pet’s health, the potential for human infection has to be considered.”
Quigley Pharma will be coordinating various protocols with the Center for Veterinary Medicine to obtain the guidance for the best route to a drug license for its potential drug. These studies shall be conducted in Biosafety Level 3 facilities across the United States and perhaps overseas.
The Quigley Corporation is the leading developer and marketer of diversified health products. The company’s proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND for human study or take any other action to allow the aforementioned compound to be marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com
The Quigley Corporation
CONTACT: Media: Karen Pineman, +1-212-725-4500, kpineman@schwartz.com, orInvestors: Carl Hymans, +1-212-725-4500, carlh@schwartz.com, both of G.S.Schwartz & Co., both for The Quigley Corporation
